权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting Latexin for radiation mitigation.

针对 Latexin 进行辐射缓解。

基本信息

批准号：
9925204
负责人：
SOMASUNDAR PRASAD GABBITA
金额：
$ 28.43万
依托单位：
P2D, INC.
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-05-06 至 2022-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9925204
关键词：
Accidents Acute Affect Animals Attention Binding Binding Proteins Biological Assay Biology Blood Blood Cells Bone Marrow Carboxypeptidase Cell Count Cell physiology Cessation of life Chemicals Dose Emergency Situation FDA approved Goals Gold Grant Granulocyte Colony-Stimulating Factor Hematologic Neoplasms Hematopoiesis Hematopoietic Hematopoietic stem cells Hemorrhage Hour In Vitro Infection Injury Ionizing radiation Lead Life Medical Metabolic Mus Natural regeneration Nuclear Accidents Nuclear Radiology PC3.1 antigen Pancytopenia Pathology Pathway interactions Pharmaceutical Preparations Pharmacology Pharmacotherapy Proteins Radiation Radiation Accidents Radiation Injuries Radiation Toxicity Radiation exposure Radiation induced damage Radio Reagent Regimen Risk Role Safety System Testing Therapeutic Tissues Toxic effect Transplantation Up-Regulation Whole-Body Irradiation Work analog base design effective therapy efficacy study experimental study functional disability genetic regulatory protein improved in vivo inhibitor/antagonist irradiation knock-down mass casualty medical countermeasure novel novel therapeutic intervention novel therapeutics pyridine radiation mitigation radiation response radiation-induced injury radiological attack screening self-renewal tissue injury

项目摘要

The purpose of this grant is to develop novel therapeutic approaches for radiological/nuclear medical countermeasures. Very few medical products have been shown to counter the acute and long-term injuries that can result from a nuclear or radiological accident or attack. Medical products and regimens that mitigate and/or treat radiation injury post-exposure (i.e., administration of first dose to start at least 24 hours after radiation exposure), with emphasis on ease of administration in a mass casualty and emergency scenario; safety; and long shelf-life are still to be developed and are thus of high priority. Therapeutic administration of a drug that inhibits the activity of the protein latexin in hematopoietic stem cells (HSCs) resulted in mitigation of HSC function. These findings suggest that pharmacologic augmentation of the activity of such a drug, in combination with additional mitigators currently developed, might offer a rational approach to the mitigation of tissue injury and lethality caused by ionizing radiation that especially affects hematopoiesis.

这笔赠款的目的是开发新的治疗方法，以治疗放射/核医学对策。很少有医疗产品被显示可对抗核爆炸或核爆炸造成的急性和长期伤害放射性事故或攻击。缓解和/或治疗的医疗产品和方案暴露后的辐射损伤(即，开始第一次剂量至少24小时辐射暴露后)，强调在大规模伤亡情况下的管理简便性和紧急情况；安全性；以及长保质期仍有待开发，因此具有高度优先级。抑制血管活性的药物的治疗性给药造血干细胞(HSCs)中的蛋白乳胶蛋白可导致HSC功能的降低。这些发现表明，这种药物活性的药理增强，与目前开发的其他缓解措施相结合，可能会提供一个合理的减轻电离辐射对组织损伤和致命性的探讨尤其会影响到造血。